Seelos Therapeutics OTC Stock Management Evaluation
| SEEL Stock | USD 0.39 0.11 22.00% |
Seelos Therapeutics employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive. Inspection of Seelos Therapeutics' management performance can provide insight into the company performance.
| Gopal Krishna Insider Head Operations |
| Michael Golembiewski Insider Chief Officer |
Seelos |
Seelos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seelos Therapeutics Workforce Comparison
Seelos Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,203. Seelos Therapeutics maintains roughly 8.0 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 2.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of (8.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $8.35. Seelos Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seelos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seelos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Seelos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mehra Raj over two months ago Acquisition by Mehra Raj of 2282262 shares of Seelos Therapeutics at 1.08 subject to Rule 16b-3 | ||
Mehra Raj over two months ago Acquisition by Mehra Raj of 75757 shares of Seelos Therapeutics at 1.32 subject to Rule 16b-3 | ||
O'connor Daniel J. over two months ago Acquisition by Oconnor Daniel J. of 50000 shares of Seelos Therapeutics subject to Rule 16b-3 | ||
Lian Brian over three months ago Insider Trading | ||
Smith Sandford D over six months ago Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | ||
Richard Pascoe over six months ago Acquisition by Richard Pascoe of 1666 shares of Seelos Therapeutics subject to Rule 16b-3 |
Seelos Therapeutics Notable Stakeholders
A Seelos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Seelos Therapeutics often face trade-offs trying to please all of them. Seelos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Seelos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gopal Krishna | Head Operations | Profile | |
| Michael Golembiewski | Chief Officer | Profile | |
| Kimberly Farrand | Senior Operations | Profile | |
| Raj JD | Chairman, Founder | Profile | |
| Anthony Marciano | Chief Officer | Profile | |
| Karen Fusaro | Senior Operations | Profile | |
| Tim MD | Chief Officer | Profile |
About Seelos Therapeutics Management Performance
The success or failure of an entity such as Seelos Therapeutics often depends on how effective the management is. Seelos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Seelos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Seelos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
The data published in Seelos Therapeutics' official financial statements typically reflect Seelos Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Seelos Therapeutics' quantitative information. For example, before you start analyzing numbers published by Seelos accountants, it's essential to understand Seelos Therapeutics' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Seelos Therapeutics Workforce Analysis
Traditionally, organizations such as Seelos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Seelos Therapeutics within its industry.Seelos Therapeutics Manpower Efficiency
Return on Seelos Therapeutics Manpower
| Revenue Per Employee | 275.4K | |
| Revenue Per Executive | 314.7K | |
| Net Loss Per Employee | 4.7M | |
| Net Loss Per Executive | 5.4M |
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.